Carmell Therapeutics Corporation (CTCX) - Total Assets
Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) holds total assets worth $3.34 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Carmell Therapeutics Corporation (CTCX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Carmell Therapeutics Corporation - Total Assets Trend (2021–2024)
This chart illustrates how Carmell Therapeutics Corporation's total assets have evolved over time, based on quarterly financial data. See net assets of Carmell Therapeutics Corporation for net asset value and shareholders' equity analysis.
Carmell Therapeutics Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Carmell Therapeutics Corporation's total assets of $3.34 Million consist of 64.8% current assets and 35.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.7% |
| Accounts Receivable | $305.93K | 20.8% |
| Inventory | $108.70K | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.64K | 1.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Carmell Therapeutics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Carmell Therapeutics Corporation market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Carmell Therapeutics Corporation's current assets represent 64.8% of total assets in 2024, an increase from 11.5% in 2021.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2024, up from 0.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 20.8% of total assets.
Carmell Therapeutics Corporation Competitors by Total Assets
Key competitors of Carmell Therapeutics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
Germany | €1.22 Trillion |
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
China | CN¥8.57 Billion |
|
Natura &Co Holding S.A.
SA:NTCO3
|
Brazil | R$34.86 Billion |
|
KP Tissue Inc
TO:KPT
|
Canada | CA$71.60 Million |
|
Suominen Oyj
HE:SUY1V
|
Finland | €278.77 Million |
|
Candles Scandinavia AB Series B
ST:CANDLE-B
|
Sweden | Skr347.00 Million |
|
Star Combo Pharma Ltd
AU:S66
|
Australia | AU$46.99 Million |
|
Mastrad
PA:ALMAS
|
France | €3.48 Million |
Carmell Therapeutics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.42 | 0.75 | 9.47 |
| Quick Ratio | 0.21 | 0.75 | 9.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.81 Million | $-1.72 Million | $1.01 Million |
Carmell Therapeutics Corporation - Advanced Valuation Insights
This section examines the relationship between Carmell Therapeutics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 3.13 |
| Asset Growth Rate (YoY) | -97.7% |
| Total Assets | $1.47 Million |
| Market Capitalization | $4.61 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Carmell Therapeutics Corporation's assets at a significant premium (3.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Carmell Therapeutics Corporation's assets decreased by 97.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual total assets of Carmell Therapeutics Corporation from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.47 Million | -97.70% |
| 2023-12-31 | $63.95 Million | +3557.25% |
| 2022-12-31 | $1.75 Million | +12.29% |
| 2021-12-31 | $1.56 Million | -- |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more